Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Albireo
Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Genetically confirmed diagnosis of Alagille syndrome
History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument
Elevated serum bile acid level
You may not be if
History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma)
History of liver transplant, or a liver transplant is planned within 6 months of randomization
ALT \>10× upper limit of normal (ULN) at screening
Total bilirubin \>15 × ULN at screening
Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome
Clareo Health | Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
